Risk Partners Life Sciences Roundtable 2024 on 18.07.24. Thank you very much! Register now for 2025 now >

No startup bonus for
criminal and administrative offenses.

As exclusively researched by Hannah SchwΓ€r and her team at Capital Magazine, the founders of Sono Motors are now also facing problems with the public prosecutor's office. According to Capital Magazin, subsidy fraud in the context of short-time work and the programs surrounding the corona crisis is in the offing. The company, which is listed on the NASDAQ via De-SPAC, has already filed a report with the SEC. While the loss amount of EUR 40,000 still seems manageable, the criminal proceedings against the two founders are much more unpleasant. Unfortunately, it does not matter that the two founders no longer work for the company. Before we go into the insurance perspective, we wish the two founders a good outcome and access to excellent criminal defense lawyers, because as partners of many growth companies and great founder personalities, our hearts "bleed" a little that the story seems to end so unpleasantly here.

What is the insurance perspective here?

It should be said in advance that Sono Motors' listing on the Nasdaq alone represents a "risk that is difficult to insure". Therefore, an effective marketing strategy is required to obtain appropriate insurance coverage. We refer interested parties to our "Road to IPO" page, where we also discuss a Nasdaq IPO. Ideally, the two founders will have access to specialized criminal liability insurance, either provided by Sono Motors or taken out privately, as well as (at least) D&O insurance.

In such cases, the preference is always for specialist criminal legal protection insurance, as it is specifically designed for such situations (which are not uncommon), whereas D&O insurance only offers a limited scope of cover to cover similar risks. Unfortunately, despite advice, we still see a low level of awareness of the issue of "unjustified" criminal investigations, particularly among growth companies, so it is not unlikely that the preferred specialist criminal legal protection insurance is not in place. In the less ideal case, the focus shifts to at least one D&O insurance policy in order to obtain insurance cover for costs (e.g. expensive criminal defense) via the criminal law section cover.

Why at least one D&O insurance policy? The special situation caused by the De-SPAC and the listing in the USA plays a role here. In addition to the challenging US capital market risk, a personal D&O or corporate D&O insurance policy without the US capital market risk, but with cover for risks in Germany, could also be available. Based on knowledge of the insurance market, it can be clearly stated that the possibly current D&O insurance with the US capital market risk, which certainly includes the company in Germany and thus the two founders, does not have to offer insurance cover despite possible negotiations on criminal law protection insurance. The background to this is that the (alleged) breaches of duty occurred before De-SPAC in 2021 and so-called De-SPAC D&O insurance policies in the USA are designed as pure "forward cover", which means that past breaches of duty are not covered. Therefore, the focus is shifting to current corporate D&O insurance policies for the "German risk" or the D&O insurance policy that was sent into run-off at the time of the listing, which should ideally be equipped with a longer grace period to step in if necessary. The same applies to any existing personal D&O insurance for the German risk (note: not available for the US capital market risk), which is certainly in run-off due to the departure of the two founders and ideally also has a correspondingly long grace period.

We hope that the two founders come out of this situation in good shape and ideally have access to high-performance special criminal legal protection insurance and - should civil law claims still arise here - also to strong cover via at least one D&O insurance policy.

Life Sciences

Finance Day 2023

Growth capital for biotechnology: Yesterday, today, tomorrow! A few days ago, Jutta Zaglauer and Florian Eckstein from our team attended the Finance Day 2023 on the occasion of the 25th anniversary of biotechnology at the IZB - Innovation and Startup Center for Biotechnology. The event offered an exciting exchange and insights into current financing and capital market issues of biotechnology companies. As an experienced specialist insurance broker for the areas of life sciences, venture capital and IPOs, all three cornerstones of our "magic expertise triangle" were part of the exciting agenda. It was also interesting to discuss the importance of customized

Read more "
Life Sciences

Atrialis GmbH - experts in clinical trial insurance

Atrialis GmbH - experts in clinical trial insurance & Risk Partners will play in the same team in the future. LifeSciences - Leading risk concepts for leading science! Under this guiding principle, we have been able to advise innovative companies from the biotechnology, pharmaceutical and medical device sectors comprehensively on risk issues for many years and support them with suitable insurance solutions in all growth and study phases, from foundation to IPO and beyond (e.g. insuring a clinical trial). Together with my team at Risk Partners GmbH, we would like to continue our focus, our passion

Read more "
Being Public

Whistleblower Protection Act

Whistleblower Protection Act ... is now in force. Hey #VCs, do you already have a system in place for safe #whistleblowing? And what about insurance cover in your D&O insurance? One month ago today, the German Whistleblower Protection Act came into force. Since July 2, 2023, not only companies with more than 50 employees, but also fund managers or ManCos (capital management companies pursuant to Section 17 (1) of the German Investment Code) are obliged to set up and operate a whistleblower system, regardless (!) of the number of employees. As of December 2

Read more "